Filing search / Innovation Pharmaceuticals Inc. / "Investigation"

8-K

EX-10.1

IPIX Innovation Pharmaceuticals Inc.

15 Jun 22

Entry into a Material Definitive Agreement

4:00pm

to the Company. 3.14 Litigation. No action, proceeding or governmental inquiry or investigation is pending or, to the best knowledge of the Company … . There is no action, suit, proceeding or investigation by the Company currently pending or that the Company intend to initiate. 3.15 No Public Offer. Neither

8-K

EX-99.1

iylla0

15 Jan 21

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives

12:35pm

8-K

EX-3.1

k6lebr4yalj

10 Dec 20

Entry into a Material Definitive Agreement

12:00am

8-K

EX-10.1

wx99fx9z1yk

10 Dec 20

Entry into a Material Definitive Agreement

12:00am

8-K

EX-10.1

za65 sgsb

4 Aug 20

Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing

9:29am

8-K

EX-4.1

2q1shalsn2jf7aqhaa

4 Aug 20

Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing

9:29am

8-K

EX-10.1

vg9d2cn1aew

22 Jul 19

Entry into a Material Definitive Agreement

9:30am

8-K

EX-3.1

4xenr3 3t

10 May 19

Entry into a Material Definitive Agreement

7:32am

8-K

EX-3.1

7944th3p oh1xcr1ks

9 Oct 18

Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline

6:52am

8-K

EX-10.1

nmnkp9th3co9buc

9 Oct 18

Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline

6:52am

8-K

EX-10.1

kzj8rp8tspxmk wvi0pu

29 Jun 18

Innovation Pharmaceuticals Announces $7 million Milestone

2:10pm